SpinTech, a Holland, Mich.-based developer of a suite of software that offers innovative advancements for brain scan MRIs, received an investment from Genesis Innovation Group’s cultivate(MD) Capital Fund II.
The amount of the deal was not disclosed.
The funds will be used to support commercialization of its first FDA cleared product while expanding pilot testing of its next generation products.
Led by Ward Detwiler, CEO, SpinTech has developed a method to collect data differently using a software processing technique that increases speed and accuracy while improving the overall workload. Its novel acquisition technique and post-processing software is designed to enhance visualization of biomarkers that they really couldn’t see in the brain before while improving throughput and accuracy, making it a significant advancement in imaging.
FinSMEs
03/12/2018